Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
50,83 SEK | +1,85% | +2,48% | +89,72% |
Omzet 2024 * | 239 mln. 22,7 mln. 21,01 mln. | Omzet 2025 * | 343 mln. 32,52 mln. 30,1 mln. | Marktkapitalisatie | 3,14 mld. 298 mln. 275 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -735 mln. -69,75 mln. -64,56 mln. | Nettowinst (verlies) 2025 * | -712 mln. -67,57 mln. -62,54 mln. | EV/omzet 2024 * | 15,1 x |
Nettoschuld 2024 * | 474 mln. 44,98 mln. 41,63 mln. | Nettoschuld 2025 * | 733 mln. 69,6 mln. 64,41 mln. | EV/omzet 2025 * | 11,3 x |
K/w-verhouding 2024 * |
-4,31
x | K/w-verhouding 2025 * |
-5,11
x | Werknemers | 166 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,64% |
Recentste transcriptie over Hansa Biopharma AB
1 dag | +2,75% | ||
1 week | +2,48% | ||
Lopende maand | +2,48% | ||
1 maand | +70,57% | ||
3 maanden | +66,11% | ||
6 maanden | +118,81% | ||
Lopend jaar | +89,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20-03-18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29-05-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 29-05-18 | |
Peter Nicklin
CHM | Chairman | 61 | 30-06-22 |
Mats Blom
BRD | Director/Board Member | 59 | 22-05-19 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
07-06-24 | 50,83 | +1,85% | 0 |
05-06-24 | 49,66 | -3,57% | 16 079 |
04-06-24 | 51,5 | -3,56% | 20 208 |
03-06-24 | 53,4 | +7,66% | 6 369 |
31-05-24 | 49,6 | +13,24% | 2 835 |
uitgestelde koers London S.E., 07 juni 2024 om 17:25 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,00% | 59,28 mld. | |
+41,42% | 40,94 mld. | |
-5,52% | 40,17 mld. | |
-5,16% | 28,69 mld. | |
+12,29% | 26,63 mld. | |
-20,85% | 18,89 mld. | |
+30,48% | 12,46 mld. | |
+0,61% | 12,42 mld. | |
+25,84% | 12,26 mld. |
- Beurs
- Aandelen
- Koers HNSA
- Koers 0RC7